Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna's projected product sales are expected to grow from $1.73 billion in 2025 to $2.15 billion in 2026, reflecting strong commercial potential and revenue growth prospects. The company has strengthened its balance sheet through a $1.5 billion debt deal, which enhances its financial flexibility to manage uncertainties and capitalize on future opportunities. Furthermore, improvements in manufacturing efficiency are anticipated to re-expand gross margins by 10% over the next three years, signaling a recovery and potential profitability enhancement following previous compressions.

Bears say

Moderna's revenue from COVID-19 vaccine sales has seen a significant decline, dropping from $18 billion in 2022 to $6.7 billion in 2023, with further downward adjustments anticipated in future revenue projections due to waning vaccination rates and increased competition from other vaccines. The firm faces additional challenges with its other pipeline programs, particularly concerning the mRESVIA vaccine for RSV, which is hindered by competition from existing vaccines, and slow progress in its therapeutic development outside of respiratory indications. As a result of these factors, long-term revenue expectations have been substantially lowered, reflecting an overall negative outlook for the company's financial growth trajectory.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.